Companies › The United Bio-Technology (Hengqin)
3 active drug programs in 8 registered trials: 3 Phase 3, 3 Phase 1, 2 Phase 2; Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| UBT251 Injection GLP-1 receptor agonist | – | Phase 3 | Type 2 Diabetes; Obesity & Overweight; Metabolic Dysfunction-associated Steatohepatitis (MASH); Obesity &Amp; Overweight … | Dec 2026 |
| UBT37034 | – | Phase 1 | Overweight , Obesity | Aug 2027 |
| UBT38006 | – | Phase 1 | Type 2 Diabetes Mellitus (T2DM) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07630233 | UBT38006 | Phase 1 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Oct 2026 |
| NCT07785934 | UBT251 Injection | Phase 1 | Drug Drug Interaction (DDI) | Metabolic and endocrine | Dec 2026 |
| NCT07145151 | UBT251 Injection | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Metabolic and endocrine | Jun 2027 |
| NCT07873645 | UBT37034 | Phase 1 | Overweight , Obesity | Metabolic and endocrine | Aug 2027 |
| NCT07659574 | UBT251 Injection | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Sep 2027 |
| NCT07648225 | UBT251 Injection | Phase 3 | Obesity & Overweight | Metabolic and endocrine | Sep 2027 |
| NCT07653477 | UBT251 Injection | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Feb 2028 |
| NCT07134335 | UBT251 Injection | Phase 2 | Obesity &Amp; Overweight | Genitourinary | Jul 2030 |
No annotated target.
–
Ascletis Pharma (China) JCR Pharmaceuticals Innovent Biologics Technology Limited (Shanghai R&D Center) Laekna Gan & Lee Pharmaceuticals.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.